DIA: Driving Insights to Action

Biosimilar Awareness, Access and Savings Continue to Grow

December 21, 2020

“As biosimilars receive FDA approval and more and more become available to patients, we're beginning to see a greater understanding and appreciation for these medicines as lower cost options,” explains Dr. Hillel Cohen, executive director of scientific affairs in the Sandoz division of Novartis and Sandoz representative to the education committee of the US Biosimilars Council. “You are not being switched to a new medication. You're being kept on the same medication that's being made by a different manufacturer.”

Podbean App

Play this podcast on Podbean App